U.S. Markets closed

Avalon GloboCare Corp. (AVCO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9248+0.0020 (+0.22%)
At close: 4:00PM EDT
Sign in to post a message.
  • Y
    Yada
    Finally done some research on this company. Every thing looks very suspicious!
    Bearish
  • M
    Mark
    Big buying happening this morning. Volume is exploding. Big news coming imo!!! $1.50+ very soon here.
    Bullish
  • M
    Mark
    I'm calling $20.00 by the end of 2021. Spike to $10+ imminent imo.
    Bullish
  • M
    Mark
    should see $1.30-1.40 today folks
    Bullish
  • Y
    Yada
    For 2020, this company spent over $4 millions in salary for 6 employees, but only spent as little as $800K in R&D. How are you suppose to accomplish anything with 800K? Not to mention all these wonderful projects they announced. Any of these projects can easily cost millions! Unless they have a magic, this may be a scam company
    Bearish
  • P
    Parbez
    Yes
    Bullish
  • T
    Trip Trap
    Due Diligence on AVCO

    *Sources listed at the bottom

    Avalon GloboCare (AVCO) is a clinical stage bio developer of cell-based technology and therapy in the sector now called Cell Tech. Avalon’s proprietary technologies are focused on the development and innovation of medicines and diagnostics to serve the strong unmet needs in cancer and other various diseases including Covid-19. Avalon has 4 different candidates in the pipeline and anyone of them could be a blockbuster.

    Founded in 2016 by means of a reverse merger they started trading on the Nasdaq in 2017. They have a 60 thousand square foot world headquarters, called the Avalon Executive Center, located in Freehold, New Jersey. Part of their corporate space is leased out to gain revenue as they build their pipeline. Avalon has also built two world-class subsidiary facilities: Avactis Biosciences and Genexosome Technologies in China. They are operating laboratories for bioproduction and standardization to produce clinical grade cells. Avalon has built up this infrastructure in anticipation of future growth.
    ----------------
    --------
    Market Cap: $104 million
    Outstanding Shares: 81 million
    Float: 25.89 million
    No debt
    Approximate cash on hand as of Sept 2020: $20 million plus
    Approximate monthly burn rate: $400,000
    Annual revenue from rental of extra commercial space: USD $1.2M. (In these early stages, Avalon for added revenue, also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in healthcare and CellTech industry markets.)
    % of shares held by insiders: 71.30%
    % of shares held by institutions: 3.46%
    Joined Russell 3000 Index in June 2019
    -----------
    -----
    Two key players for Avalon:

    1. CEO - Dr. David Jin, M.D., Ph.D.
    Dr. Jin was the CMO of BioTime from 2009 to 2016. He served as the physician/scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University.

    Dr. Jin is a CEO who knows the "ins and outs" of pharmaceutical investment and innovation. As the principal investigator of more than 15 pre-clinical and clinical studies, he authored over 80 peer-reviewed medical publications.

    With his background as the faculty of internal medicine, hematology, and clinical oncology at the New York-Presbyterian Hospital (NYPH), he trained a breadth of talents from Cornell and Columbia Universities.
    Dr. Jin also garnered recognition receiving two prestigious awards as the Top Chief Medicall Officer by ExecRank in 2012 and Leading Physicians of the World in 2015.

    Dr. Jin owns 15,766,667 shares of AVCO which is 19.1% of the common stock

    2. Chairman of the Board – Mr. Wenzhao (Daniel) Lu
    Chairman Lu is a seasoned healthcare entrepreneur with extensive operation in China. He has also been serving as Chairman of the Board for the Lu Daopei Medical Group in China since 2010.
    Under his leadership, the Lu Daopei Medical Group has recently expanded its clinical network involving a state-of-the-art stem cell bank at Wuhan Biolake, three top-ranked private hospitals (located in Beijing, Shanghai, and Hebei), specialty hematology laboratories, as well as a hematology research institute, with more than 100 partnering and collaborating hospitals in China.

    Chairman Lu received a Bachelor of Arts from Temple University Tyler School of Arts in 1988 and subsequently worked as senior Art Director at Ogilvy & Mather Advertising Company. Prior to joining Lu Daopei Medical Group, Chairman Lu served as Chief Operating Officer for BioTime Asia Limited which is a subsidiary of BioTime, Inc. (NYSE/AMEX:BTX) in 2009.

    Chairman Lu is a multimillionaire with deep pockets and vast connections in biotech. He is AVCO’s largest shares holder with 29,400,000 shares which is 35.6% of the common stock. This leaves him highly motivated to keep AVCO free from cash flow constraints and this money reserve is a huge advantage that Avalon has over competitors.
    -----------
    -----
    Key Partnerships / Relationships: Avalon has put in place a way to accelerate its product development and commercialization through strategic working relationships.

    GE Healthcare - On June 22, 2019, Avalon announced a highly strategic partnership with GE Healthcare. This partnership will allow Avalon to ramp up cell therapy production, streamline the whole development/commercialization process and allow Avalon to conquer the vast cellular therapy market in China while building its footprints worldwide.

    Weill Cornell Medicine - On October 9th, 2018 Weill Cornell Medicine selected Avalon’s subsidiary, Genexosome Technologies, proprietary exosome isolation system as a key component in the world’s first standardization processing of cGMP-grade exosomes for clinical studies. "This strategic co-development endeavor will synergize Genexosome Technologies’ top-rated isolation platform with Weill Cornell’s world-class cGMP cellular therapy/cell-derived product processing facil
  • D
    Datesy
    Any good news will send this thing higher. Really need some good PR
  • T
    Trip Trap
    AVCO is on the launch pad (yes...I was about a month early on my last call and big enough to admit it.)

    Yesterday, Wed 8/12, was a significant day for AVCO.

    A huge sideways coiling price action has occurred over the last 4 months. This type of action is often a precursor to a big move. Newbies get bored and bailout. Pros load up on the dips (as long as the fundamentals/management/stock structure are solid like they are for AVCO)

    The OBV (On Balance Volume indicator) broke out yesterday to the upside from the nearly 4 month sideways coiling price action. Will price soon follow? It often does....

    The 10 EMA just crossed up and above the 50 EMA...

    Yesterday's low tested the recent breakout area around the 50 day EMA. Last Wednesday's low 8/5 took out the critical shelf of support (and stop loss orders) at 1.52 formed over the last 4 months and then popped right back up again forming a doji candle stick...The low on that day was 1.50...we have done nothing but go up since then...

    We have had above average volume over the last 3 days. These included two huge separate buy orders you can see if you look at a 5 min chart this past Monday and Wednesday. Someone with a lot of money is accumulating this stock below $2.00.

    Many many positive fundamentals in the works along with excellent management and share structure.

    We just need to make a solid close up above the critical $1.80. If this occurs we should see a very large upward move develop. First target would be the $2.50 area. Then $5.00 to fill in the huge gap left back on April 25th 2019. Then the target of $13.00, the all time high, and then who knows from there but potentially much higher.

    Things could get interesting here soon for AVCO!

    This is my opinion...do your own due diligence!
  • b
    bear hunter
    Much of the innovation surrounding healthcare stocks focuses on development of new drug candidates, therapies, diagnostics and devices…
    Much of the innovation surrounding healthcare stocks focuses on development of new drug candidates, therapies, diagnostics and devices…
    medium.com
  • L
    Left Brain
    I bought 1000 shares few days ago at $3.70 nothing thinking much of it. And now it is at $12.75? Any reason for this to go up this much quickly in few days?
  • a
    art
    2/11/19-Avalon GloboCare-- Announces Breakthrough in Identifying Human Angiogenic Exosomes/Extracellular Vesicles (EV) Derived from Endothelial Cells
    February 11, 2019 (Globe Newswire) "Considered by many the "HOLY GRAIL"-in this area"--
    Angiogenic exosomes containing angiogenic factors developed to promote new blood vessel formation and tissue regeneration upon release from exosomes.

    Results from Avalon's co-development program with Weill Cornell Medicine led by Yen-Michael Hsu, M.D., Ph.D., Director of cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering.

    Accepted as podium presentation at the International Society of Extracellular Vesicles (ISEV) 2019 Annual Meeting, Kyoto, Japan.

    Avalon GloboCare Corp. (NASDAQ:AVCO) (NASDAQ listed Avalon GloboCare AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that its ongoing co-development program with Weill Cornell Medicine, led by Yen-Michael Hsu, M.D., Ph.D., Director of cGMP Cellular Therapy Facility and Laboratory for Advanced Cellular Engineering, has identified novel human angiogenic exosomes/extracellular cellular vesicles (EV) derived from endothelial cells. These angiogenic exosomes contain angiogenic factors developed to promote new blood vessel formation and tissue regeneration upon release from exosomes. A podium presentation titled "Novel Angiogenic Extracellular Vesicles Induced by StemReginin1" will be presented by Dr. Hsu at the upcoming Annual ISEV Meeting in Kyoto, Japan.

    "Identification and isolation of tissue-specific exosomes is considered by many as the "Holy Grail" in this area," stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare. "This discovery is essential for future development of endothelial cell-derived angiogenic exosomes in treating ischemic vascular diseases, as well as contribution to tissue and organ regeneration," added Dr. Jin.
  • J
    J
    I'm in 3000 shares on this stock, and currently in the red. I had high hopes for this one but seems even when good news is released, it causes the stock to go down instead of up. WTH? Im in it for the long haul but getting anxious since it is a very hum drum stock to watch while others shoot up all around it. I am just hoping this one does as well.
  • D
    Daryor
    I think it’s time to load up . IMO
  • p
    phan
    This company is hush hush about tomorrow. I am sure the news will be positive because it’s their largest conference and want the shock factor. There is no insider trades since April when a director purchased 645k shares. It looks like it’s moving a bit today on low volume.
  • w
    william
    predictions?
  • a
    art
    Avalon GloboCare CEO David Jin, M.D., Ph.D. to Chair and Speak at the Plenary Session of the 14th Annual World Stem Cell Summit
    January 15, 2019 (Globe Newswire) Print

    Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that its President and Chief Executive Officer, David Jin, M.D., Ph.D., will chair and speak at the plenary session of the 14th Annual World Stem Cell Summit in Miami, Florida. The presentation is entitled, "Status of Cellular Therapy and Regenerative Medicine in China."
  • C
    Craig
    I am a new investor and am wondering what you all think is going to happen with this stock?
  • L
    Larry
    7 full time employees?
  • s
    some one :-) imp ?
    Big day this run is not over !!!